Every S-1 that Propanc Biopharma, Inc. (PPCB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow PPCB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PPCB filings page.
Propanc Biopharma, Inc. is registering up to 2,500,000 shares of Common Stock for resale by Hexstone Capital LLC. These shares are issuable upon conversion of up to 9,900 shares of Series C Preferred Stock that may be acquired through a warrant.
Propanc already received $1,000,000 in gross proceeds from issuing 100 Series C Preferred shares and the warrant, and would receive up to $99,000,000 more if the warrant is fully exercised for cash. The company will not receive proceeds from selling stockholder resales. The Series C converts at the lesser of $125.00 or 85% of a volume-based market price, floored at $12.50, subject to a 4.99% (or 9.99% on notice) beneficial ownership cap and a 9,500,000-share reserve.
Shares outstanding were 3,503,116 as of July 6, 2026, or 6,003,116 if all registered shares are issued. Propanc reports no revenue, a nine‑month net loss of $15,221,714, an accumulated deficit of $140,843,234, cash of $443,702, and substantial doubt about its ability to continue as a going concern.
Propanc Biopharma, Inc. has filed a resale registration statement covering up to 15,000,000 shares of common stock for a single selling stockholder, Hexstone Capital LLC. These shares are issuable upon conversion of Series C Preferred Stock already issued or issuable under a warrant.
The company will not receive proceeds from any resale of these shares, only from potential future cash exercises of the warrant. Propanc is a development‑stage oncology company focused on its lead candidate PRP for pancreatic, ovarian and colorectal cancers, with no revenue, large accumulated losses, and substantial doubt about its ability to continue as a going concern absent new capital.
Propanc Biopharma, Inc. has filed an amended Form S-1 registering the resale of up to 7,000,000 shares of common stock by a single selling stockholder. These shares are issuable upon conversion of 100 outstanding shares and up to 9,900 warrant-exercisable shares of Series C Preferred Stock.
The company will not receive proceeds from the resale, but would receive cash if the Series C warrant is exercised, with potential gross proceeds of approximately $99,000,000.00. An earlier private placement generated about $1,000,000.00 in gross proceeds. Common shares outstanding were 15,091,133 as of January 26, 2026, rising to 22,091,133 if all registered shares are sold.
Propanc is a development-stage biotech focused on its lead cancer candidate PRP and discloses substantial doubts about its ability to continue as a going concern, given no revenues, large accumulated deficits and reliance on external financing. The company is a smaller reporting and controlled company, highlighting extensive risks around liquidity, dilution, volatility and speculative nature of its stock.
Propanc Biopharma, Inc. is registering up to 7,000,000 shares of common stock for resale by a single selling stockholder. These shares are issuable upon conversion of 100 outstanding shares of Series C Preferred Stock and up to 9,900 additional Series C Preferred shares underlying a warrant.
The resale relates to a prior $1,000,000 private placement with Hexstone Capital LLC; Propanc will not receive proceeds from stockholder sales, but would receive cash if the $10,000-per-share warrant is exercised, potentially up to $99,000,000. Each preferred share converts at the lesser of $5.00 or 85% of a market-based price, floored at $0.50, subject to 4.99% (optionally 9.99%) beneficial ownership limits. Shares outstanding were 15,091,133 as of January 26, 2026, and would be 22,091,133 if all registered shares are sold. The company is a development-stage oncology business focused on its PRP candidate, reports large recurring losses, has substantial doubt about its ability to continue as a going concern, carries defaulted debt, and warns of significant dilution, volatility, and control by its CEO through preferred stock voting power.
Propanc Biopharma, Inc. is registering up to 2,000,000 shares of common stock for resale by a single selling stockholder, Hexstone Capital LLC. These shares underlie 100 initially issued shares of Series C Preferred Stock and up to 9,900 additional Series C Preferred shares issuable upon exercise of a warrant. Propanc will not receive any proceeds from the resale, but would receive cash if the warrant is exercised.
Each Series C Preferred share has a stated value of $10,000 and converts into common stock at the lesser of a fixed $5.00 per share or 85% of a market-based price, subject to a 4.99% beneficial ownership cap that may be increased to 9.99% with notice. The company previously raised approximately $1,000,000 in gross proceeds from this preferred stock financing and may use funds for working capital, product development, and general corporate purposes.
Propanc is a development-stage oncology company focused on its lead anti-cancer candidate PRP for pancreatic, ovarian, and colorectal cancers, has no revenue-generating operations and an accumulated deficit, and discloses substantial doubt about its ability to continue as a going concern without additional capital. As of December 15, 2025, it had 13,364,244 common shares outstanding and would have 15,364,244 shares if all registered shares are issued and sold, and it qualifies as both a smaller reporting company and a controlled company under Nasdaq rules.